Latchman Y, Wood CR, Chernova T, et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation.
Nat Immunol. 2001;2(3):261-268.
Taube JM, Klein A, Brahmer JR, et al. Association of PD-1, PD-1 ligands, and other features of the tumor
immune microenvironment with response to anti–PD-1 therapy. Clin Cancer Res. 2014;20(19):5064-5074.
Rozali EN, Hato SV, Robinson BW, Lake RA, Lesterhuis WJ. Programmed death ligand 2 in cancer-induced immune
suppression. Clin Dev Immunol. 2012. doi:10.1155/2012/656340.
Youngnak P, Kozono Y, Kozono H, et al. Differential binding properties of B7-H1 and B7-DC to programmed
death-1. Biochem Biophys Res Commun. 2003;307(3):672-677.
Calles A, Liao X, Sholl LM, et al. Expression of PD-1 and its ligands, PD-L1 and PD-L2, in smokers and
never smokers with KRAS-mutant lung cancer. J Thorac Oncol. 2015;10(12):1726-1735.
Vanderstraeten A, Luyten C, Verbist G, Tuyaerts S, Amant F. Mapping the immunosuppressive environment in
uterine tumors: implications for immunotherapy. Cancer Immunol Immunother. 2014;63(6):545-557.
Liu J, Liu Y, Wang W, Wang C, Che Y. Expression of immune checkpoint molecules in endometrial carcinoma.
Exp Ther Med. 2015;10(5):1947-1952.
Shi M, Roemer MG, Chapuy B, et al. Expression of programmed cell death 1 ligand 2 (PD-L2) is a
distinguishing feature of primary mediastinal (thymic) large B-cell lymphoma and associated with PDCD1LG2
copy gain. Am J Surg Pathol. 2014;38(12):1715-1723.